Anzeige
Mehr »
Login
Donnerstag, 28.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Spezial am Donnerstag: Rallye II. - Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
279 Leser
Artikel bewerten:
(1)

Diabetic Foot Ulcer Treatment Market Expected to Witness a High Jump as the Market is Projected to Grow with a CAGR of 17.0% During the Study Period (2018-2030) | DelveInsight

The Diabetic Foot Ulcer market is expected to grow due to an increase in diabetes cases, expected entry of emerging therapies, and readily adoption of these novel therapies.

LAS VEGAS, March 1, 2021 /PRNewswire/ -- DelveInsight's "Diabetic Foot Ulcer (DFU) Market" report provides a thorough comprehension of the Diabetic Foot Ulcer, historical and forecasted epidemiology, and the Diabetic Foot Ulcer market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan]. The Diabetic Foot Ulcer market report also proffers an analysis of recent Diabetic Foot Ulcer treatment algorithm/practice, market drivers, market barriers, and unmet medical needs.

DelveInsight_Logo

Some of the vital points of the Diabetic Foot Ulcer Market Research Report

  • Diabetic Foot Ulcer (DFU) is one of the most significant and devastating complications of diabetes mellitus, and probably the major component of the diabetic foot. According to American Podiatric Medical Association (APMA), diabetes is the leading cause of non-traumatic lower extremity amputations in the United States, and approximately 14-24% of patients with diabetes who develop a foot ulcer will require an amputation. Foot ulceration precedes 85% of diabetes-related amputations.
  • The gold standard for Diabetic Foot Ulcer treatment includes debridement of the wound, management of any infection, revascularization procedures when indicated, and off-loading of the ulcer. Currently, the market is mainly dominated by off-label generic drugs such as analgesics and anti-infectives, around 78% of the current market is captured by these two classes of drugs.
  • There is only one drug, Regranex (Becaplermin), which the FDA has approved. Regranex gel uses a Platelet-derived growth factor (PDGF) for the Diabetic Neuropathic Ulcer treatment formulated to act as a first-line treatment following effective ulcer care. The US FDA had approved the biologics license application of Becaplermin (OMJ Pharmaceuticals, Inc) in December 1997.
  • Market players such as Amniox (TissueTech), Helixmith Co., Ltd., Oneness Biotech Co., Ltd., Ticeba GmbH, RHEACELL GmbH & Co. KG, and Lakewood-Amedex Inc, Aurealis Therapeutics, Biotherapy Services, Microbion Corporation, Mallinckrodt, and many others are involved in developing Diabetic Foot Ulcer drugs.
  • The emerging therapies under development expected to provide efficient therapeutic approaches with a novel mechanism of action to treat Diabetic Foot Ulcer patients. Among the emerging therapies, cryopreserved umbilical cord TTAX01 allograft from Amniox Medical (a TissueTech) is expected to garnerthe highest patient share owing to promising efficacy signals shown in phase II trial and the company is well on track with two-phase III multicenter randomized controlled clinical trials.

For additional information on Market Impact by Therapies, visit: Diabetic Foot Ulcer Treatment Market Analysis

A Diabetic Foot Ulcer is a complex chronic wound commonly in type 1 and type 2 diabetes mellitus patients. Diabetes patients can quickly develop foot ulcers and foot pain as they are a common complication of poorly controlled diabetes, but good foot care can help prevent them. As per DelveInsight's analysis, the total Diabetic Foot Ulcer prevalent cases were 5,994,978 cases in the 7MM (the United States, EU5 [Germany, France, Italy, Spain, and the United Kingdom], and Japan) in 2020 and are expected to grow during the study period of 2018-2030.

For more information on Diabetic Foot Ulcer Market, click here @ Diabetic Foot Ulcer Market Infographic

The DFU Market Report provides historical as well as forecasted epidemiological analysis segmented into:

  • Total Prevalent Cases of Diabetic Foot Ulcer
  • Total Diagnosed Cases of Diabetic Foot Ulcer
  • Gender-specific cases of Diabetic Foot Ulcer
  • Age-specific Cases of Diabetic Foot Ulcer
  • Diabetic Foot Ulcer cases by severity/chronicity of wound
  • Treated cases of Diabetic Foot Ulcer

Request sample report for more insights @ Diabetic Foot Ulcer Market Size

Diabetic Foot Ulcer Therapeutics Market

The therapy goals for Diabetic Foot Ulcer patients are wound closure, eradication of clinical evidence of infection, and the avoidance of soft tissue loss and amputations.

Currently, Diabetic Foot Ulcer treatment strategies mainly include non-surgical treatment for mild and moderate ulcers and surgical treatment for ulcers classified as severe. Non-surgical treatment options mainly include simple daily wound care, using growth factors and skin substitutes for wound repair, antibiotics for the deep infection, drainage, and cellulitis. Whereas surgical treatment options mainly include debridement, removal of unhealthy tissue, and vascular surgeries to induce better blood flow. The development of growth factor for treatment represents a significant therapeutic advance for diabetic neuropathic foot ulcers with adequate blood supply.

Platelet-derived growth factor (PDGF) is one of the primary growth factors involved in healing. Regranex (Becaplermin) is the only drug, which uses PDGF and is approved by the US FDA. Regranex (Becaplermin) is a topical gel labeled for adjunctive treatment of stage III and IV diabetic neuropathic ulcers of the lower extremities. Becaplermin is a recombinant human platelet-derived growth factor; therefore, it promotes wound healing by enhancing granulation tissue formation. This recombinant growth factor is delivered in a topical aqueous-based sodium carboxymethylcellulose (NaCMC) gel. Regranex gel is used to treat diabetic neuropathic ulcers, formulated to act as a first-line treatment following effective ulcer care.

Diabetic Foot Ulcer Emerging Therapies Along with Key Players

The companies are working to assess challenges and seek opportunities that could influence Diabetic Foot Ulcer R&D. The therapies under development are focused on novel approaches to treat Diabetic Foot Ulcer. Major players are involved in developing Diabetic Foot Ulcer therapies.

  • TTAX01 (Neox Cord 1K): Amniox (TissueTech)
  • Engensis (VM202; Donaperminogene Seltoplasmid): Helixmith
  • ON101 (WH-1): Oneness Biotech
  • Allo-APZ2-DFU (ABCB5 positive MSCs): Rheacell (a subsidiary of Ticeba)
  • Bisphosphocin Nu-3: Lakewood-Amedex
  • AUP1602-C: Aurealis Therapeutics
  • RAPID Biodynamic PRP Haematogel: Biotherapy Services
  • MBN-101 (Pravibismane): Microbion Corporation
  • ExpressGraft (C9T1 Skin Tissue): Mallinckrodt

And many others.

Concluding thoughts on Diabetic Foot Ulcer Market Growth Dynamics

The dynamics of the Diabetic Foot Ulcer market are anticipated to change in the coming years because of the DFU Market Drivers such as an increase in diabetes cases, a rich emerging pipeline, the development of new treatment modalities, and increased awareness across health care systems. However, the burden of high cost in Diabetic Foot Ulcer treatment, post-operative challenges in Diabetic Foot Ulcer patients, and unavailability of specialists lead to restraints in Diabetic Foot Ulcer market growth.

Scope of the Diabetic Foot Ulcer Market Insight Report

  • Geography Covered: 7MM - The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan.
  • Study Period: 3-year historical and 10-year forecasted analysis (2018-2030).
  • Diabetic Foot Ulcer Markets Segmentation: By Geographies and By Diabetic Foot Ulcer Therapies (Historical and Forecasted, Current and Upcoming)
  • Leading Market Companies investigating its candidates for Diabetic Foot Ulcer: Amniox (TissueTech), Helixmith Co., Ltd., Oneness Biotech Co., Ltd., Ticeba GmbH, RHEACELL GmbH & Co. KG, and Lakewood-Amedex Inc, Aurealis Therapeutics, Biotherapy Services, Microbion Corporation, Mallinckrodt, and several others.
  • Analysis: Comparative and conjoint analysis of emerging therapies.
  • Case Studies
  • KOL's Views
  • Analyst's View

Request for a Webex demo of the report @Global Diabetic Foot Ulcer Treatment Market Size

Table of Contents

1

Key Insights on Diabetic Foot Ulcer

2

Executive Summary of Diabetic Foot Ulcer

3

SWOT Analysis of Diabetic Foot Ulcer

4

Diabetic Foot Ulcer Market Share (%) Distribution Overview at a Glance: By Country

5

Diabetic Foot Ulcer Epidemiology and Market Methodology

6

Disease Background and Overview: Diabetic Foot Ulcer

7

Diabetic Foot Ulcer Diagnosis

8

Prevention of Diabetic Foot Ulcer

9

DFU Diagnostic Guidelines

10

Diabetic Foot Ulcer Epidemiology and Patient Population

11

Diabetic Foot Ulcer Epidemiology Scenario: 7MM

12

United States DFU Epidemiology

13

EU5 Countries DFU Epidemiology

13.1

Germany

13.2

France

13.3

Italy

13.4

Spain

13.5

United Kingdom

14

Japan DFU Epidemiology

15

Current DFU Treatment Practices

16

Diabetic Foot Ulcer Treatment and Prevention Guidelines

17

Unmet Needs

18

Patient Journey of Diabetic Foot Ulcer

19

Key Endpoints in DFU Clinical Trials

20

Diabetic Foot Ulcer Marketed Therapy

20.1

Regranex Gel (Becaplermin): Smith & Nephew

21

Diabetic Foot Ulcer Emerging Therapies

21.1

TTAX01 (Neox Cord 1K): Amniox (TissueTech)

21.2

Engensis (VM202; Donaperminogene Seltoplasmid): Helixmith (formerly

known as ViroMed)

21.3

ON101 (WH-1): Oneness Biotech

21.4

Allo-APZ2-DFU (ABCB5 positive MSCs): Rheacell (a subsidiary of Ticeba)

21.5

Bisphosphocin Nu-3: Lakewood-Amedex

21.6

AUP1602-C: Aurealis Therapeutics

21.7

RAPID Biodynamic PRP Haematogel: Biotherapy Services

21.8

MBN-101 (Pravibismane): Microbion Corporation

21.9

ExpressGraft (C9T1 Skin Tissue): Mallinckrodt

22

7MM Diabetic Foot Ulcer Market Analysis

23

7MM Diabetic Foot Ulcer Market Size

24

United States Diabetic Foot Ulcer Market Size

25

EU-5 Diabetic Foot Ulcer Market Size

25.1

Germany Market Size

25.2

France Market Size

25.3

Italy Market Size

25.4

Spain Market Size

25.5

United Kingdom Market Size

26

Japan Diabetic Foot Ulcer Market Size

27

Market Access and Reimbursement of Diabetic Foot Ulcer Therapies

28

Diabetic Foot Ulcer Market Drivers

29

Diabetic Foot Ulcer Market Barriers

30

Appendix

31

DelveInsight Capabilities

32

Disclaimer

33

About DelveInsight

Browse detailed TOC with charts, figures, tables @ DFU Market Size Report

View Related Reports

  • Diabetic Foot Ulcers Epidemiology Forecast Analysis

DelveInsight's Diabetic foot ulcers (DFUs) - Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Diabetic foot ulcers (DFUs) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

  • Diabetic Foot Ulcers Pipeline Analysis

Diabetic Foot Ulcers Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Diabetic Foot Ulcers market.

  • Dementia with Diabetes Market Analysis

DelveInsight's Dementia with Diabetes - Market Insights, Epidemiology and Market Forecast - 2030 report provides an in-depth understanding of historical and forecasted epidemiology.

  • Diabetes Market Analysis

DelveInsight's Diabetes Market Insights, Epidemiology and Market Forecast - 2030 report provides thorough insights on epidemiology and market trends.

  • Diabetic Foot Market Analysis

DelveInsight's Diabetic Foot - Market Insights, Epidemiology, and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.

  • Diabetic Gastroparesis Market Analysis

Diabetic Gastroparesis Market Research Report presents a detailed analysis of the market listing Diabetic Gastroparesis Epidemiology, Drug therapies.

  • Diabetic Ketoacidosis Market Analysis

DelveInsight's Diabetic Ketoacidosis (DKA) - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.

  • Diabetic Kidney Disease Market Analysis

DelveInsight's Diabetic Kidney Disease (DKD) - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.

  • Diabetic Macular Edema Market Analysis

DelveInsight's Diabetic Macular Edema (DME) - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.

  • Diabetic Nephropathy Market Analysis

DelveInsight's Diabetic Nephropathy - Market Insights, Epidemiology, and Market Forecast - 2030 report provides a detailed overview of the disease.

  • Diabetic Neuropathy Market Analysis

DelveInsight's "Diabetic Neuropathy - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of Diabetic Neuropathy, historical and forecasted epidemiology.

  • Diabetic Peripheral Neuropathy Market Analysis

DelveInsight's Diabetic Peripheral Neuropathy - Market Insights, Epidemiology and Market Forecast - 2030 report provides an in-depth understanding of historical and forecasted epidemiology.

  • Diabetic Retinopathy Market Analysis

DelveInsight's Diabetic Retinopathy Market Insights, Epidemiology and Market Forecast 2030 report provides an overview of the disease & understanding of historical & forecasted epidemiology.

  • Diabetes Pen Market Analysis

Diabetes Pen Market Insights, Competitive Landscape and Market Forecast-2025 report delivers an in-depth understanding of the Diabetes Pen Market and the historical and forecasted epidemiology.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact Us:

Shruti Thakur
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg

Großer Dividenden-Report 2024 von Dr. Dennis Riedl
Der kostenlose Dividenden-Report zeigt ganz genau, wo Sie in diesem Jahr zuschlagen können. Das sind die Favoriten von Börsenprofi Dr. Dennis Riedl
Jetzt hier klicken
© 2021 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.